ArticleBiomarkers in medicine2009
Biomarkers of HIV-1-associated neurocognitive disorders: challenges of proteomic approaches.
Article in Biomarkers in medicine, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 10 citations in OpenAlex.
- Proteomics, biomarkers, and HIV-1: A current perspective.Proteomics. Clinical applications · 2016Review
- Reduced neural specificity in middle-aged HIV+ women in the absence of behavioral deficits.NeuroImage. Clinical · 2015Article
- Changes in PINCH levels in the CSF of HIV+ individuals correlate with hpTau and CD4 count.Journal of neurovirology · 2014Article
- Comparison of 4-plex to 8-plex iTRAQ quantitative measurements of proteins in human plasma samples.Journal of proteome research · 2012Article
- Article
- Immunoreactivity of anti-gelsolin antibodies: implications for biomarker validation.Journal of translational medicine · 2010Article
- Plasma proteomic analysis of simian immunodeficiency virus infection of rhesus macaques.Journal of proteome research · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
HIV-1 enters the brain shortly after infection, which may lead to neurological complications and in the most severe cases to encephalitis, dementia and death. The introduction of antiretroviral therapy reduced the incidence of the most severe conditions, nevertheless, approximately half of those infected with this virus will suffer to various degrees from HIV-1-associated neurocognitive disorders. Despite many years of research, there are no biomarkers that can objectively measure and, more importantly, predict the onset and the tempo of HIV-1-associated neurocognitive disorders. Here we review biomarker candidates of neurocognitive impairment due to HIV infection of the brain that have been proposed during the last two decades, and discuss perspectives and limitations of proteomic approaches in the search for new, more sensitive and specific biomarkers.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.